Anika Therapeutics (ANIK) Gross Profit (2010 - 2026)

Anika Therapeutics (ANIK) has 17 years of Gross Profit data on file, last reported at $19.0 million in Q1 2026.

• Gross Profit for Q1 2026 came in at $19.0 million, up 29.4% year-over-year; the trailing twelve-month figure through Mar 2026 was $68.1 million (down 4.99% YoY), and the FY2025 annual result was $63.8 million, down 16.04% from the prior year.
• Gross Profit slipped to $19.0 million in Q1 2026 per ANIK's latest filing, from $19.2 million in the prior quarter.
• Over five years, Gross Profit peaked at $29.0 million in Q2 2023 and troughed at $3.8 million in Q4 2022.
• A 5-year average of $18.5 million and a median of $19.2 million in 2025 frame the typical range for Gross Profit.
• The sharpest annual moves came in 2022 and 2024: Gross Profit plunged 79.18% in 2022, then surged 196.66% in 2024.
• A 5-year view of Gross Profit shows it stood at $3.8 million in 2022, then jumped by 52.93% to $5.8 million in 2023, then soared by 196.66% to $17.1 million in 2024, then increased by 11.99% to $19.2 million in 2025, then slipped by 0.95% to $19.0 million in 2026.
• Business Quant data shows ANIK's Gross Profit at $19.0 million in Q1 2026, $19.2 million in Q4 2025, and $15.6 million in Q3 2025.